H epatocellular carcinoma surveillance is recommended by all 3 major hepatology societies. [1] [2] [3] Nevertheless, surveillance rates remain well below 50%, and in some populations as low as 12%. [4] [5] [6] [7] Among the many steps needed for surveillance to be accomplished, physician education and incorporation of surveillance into their practice are critical. As expected, hepatologists and gastroenterologists tend to believe in surveillance and are more likely to order it routinely for their cirrhotic patients, 5, 7 but only 20% to 50% of such patients are seen by such subspecialists. 7, 8 Primary care providers (PCPs) see most of the remainder.
Therefore, if surveillance is to have any chance of reaching more than 50% of cirrhosis patients, enlistment of PCPs will be necessary. Only 3 studies have investigated the practice and knowledge of hepatocellular carcinoma (HCC) surveillance among PCPs and these 3 studies focused primarily on PCPs who see a high number of Asian patients or on surveillance for viral hepatitis rather than HCC surveillance.
9-11 Therefore, we sampled PCPs from the entire North Carolina Medical Board database and limited our questionnaire to HCC surveillance only.
Abbreviations used in this paper: AFP, a-fetoprotein; HCC, hepatocellular carcinoma; PCP, primary care provider; RCT, randomized controlled trial; US, ultrasound.
Methods

Institutional Review of Research
Our research project and protocol were reviewed and approved by the University of North Carolina Institutional Review Board before initiating this study.
Subjects
We used the North Carolina Medical Board database to identify practicing PCPs (physicians and doctors of osteopathy) in North Carolina. A random sample of 1000 PCPs was identified. This sample represented 14% of North Carolina PCPs.
12,13
Survey
Survey methodology was based on the tailored design method.
14 All subjects received an introductory letter, followed by the questionnaire in a separate mailing. The questionnaire consisted of 8 items addressing knowledge and use of HCC surveillance guidelines, as well as identification of HCC therapies. Basic demographics and practice information requested was limited to gender, years in practice, major affiliations (eg, academic facility, Veterans Affairs, private practice), and their ability to see Medicaid-covered patients. We purposely did not request more specific information that would lengthen the questionnaire, compromise anonymity, and potentially decrease the response rate. Therefore, we did not collect information on practice location, type of service area (rural vs urban), training or specific type of practice (ie, group vs solo, family practice vs internal medicine). Such limiting of variables did not allow us to construct a conceptual behavioral model for the decision to recommend surveillance. Instead, we focused on the self-reported rate of surveillance, and the modality and interval recommended. We also asked about knowledge of HCC therapies because they have changed substantially in the past decade and remain a primary justification for surveillance. No pretesting or validation of this brief survey were performed. A $10 cash incentive was included to reduce nonresponse bias and was given regardless of whether the PCP completed the questionnaire or not. A reminder/gratitude postcard was mailed to all subjects, followed by the mailing of a second questionnaire for nonresponders. An addressed return envelope with prepaid postage was included.
To ensure anonymity, all questionnaires were given an alphanumeric code. The master key linking the code to the subject name was used only at the time of mailing and receipt portion of the study to determine who should receive a second-chance mailing. Data collection (receipt of questionnaires) was closed 90 days after the last mailing was completed. Thereafter, the master key was destroyed and no further questionnaires were collected or mailed out.
Analysis
Demographic, practice information, and survey responses were analyzed using basic descriptive statistics (eg, means, medians, proportions, standard deviations). We used the Pearson chi-square and t tests where appropriate to compare PCPs who screened and those who did not. Logistic regression was used to identify independent variables associated with surveillance.
Results
Subjects: Primary Care Providers
Of the 1000 PCPs to whom we mailed letters and questionnaires, 391 (39%) completed the questionnaire and mailed it back to us. Two PCPs answered questions in an incongruent or unclear manner and had to be discarded (1 PCP indicated not seeing cirrhotic patients yet performed surveillance; another did not answer whether they saw cirrhotic patients but indicated they do not screen). Characteristics of the remaining 389 PCPs are shown in Table 1 . The vast majority was in private practice and saw Medicaid patients. Nearly 90% saw cirrhotic patients in their practices.
Hepatocellular Carcinoma Surveillance
Of the 345 PCPs who saw cirrhotic patients, only 45% recommended HCC surveillance. There were no significant differences between those PCPs who do recommend surveillance (n ¼ 156) from those who do not (n ¼ 189) in terms of gender years in practice, practice affiliation, and whether they see Medicaid patients. The most common means of surveillance used was liver ultrasound and a-fetoprotein (AFP) measurement ( Figure 1 ). The most common interval for surveillance was 12 months (Figure 2 ). Nearly three quarters of those who provide surveillance do so because they believed evidence supported it (Table 2) . When asked to identify barriers to surveillance, 54% identified poor patient adherence and 53% identified patient financial constraints, 49% identified lack of insurance, and 32% identified insurance constraints on coverage. Only 5% identified lack of available surveillance services (eg, radiology) as a barrier.
Among those who do not recommend surveillance, the vast majority (84%) defer to subspecialists to decide or perform surveillance (Table 3) . However, 46 (24%) were unaware of any surveillance recommendations, and only 15 (8%) believed the benefit of surveillance was uncertain. Only 4% identified cost as a reason for not recommending surveillance.
Knowledge of Hepatocellular Carcinoma Therapies and Association With Surveillance
Of the 345 PCPs who see cirrhosis patients, 230 (67%) identified resection as an effective therapy for HCC, but only 192 (56%) identified liver transplant (Table 4) . Other effective treatments were identified less frequently. PCPs who were able to identify at least one modality as an effective therapy were more likely to screen, with an odds ratio of 1.9 (P ¼ .04). On multivariate analysis (controlling for PCP gender, practice setting, years in practice, and whether they see Medicaid patients), the association between identifying at least one effective therapy and recommending surveillance remained significant (odds ratio, 2.1; 95% confidence interval, 1.1-4.0). None of the other ˇ O ther category for interval: 2 PCPs provided ranges of 6 to 12 months, 5 PCPs indicated taking cues from subspecialists, and 8 PCPs provided unclear answers for interval (eg, "depends" and "periodically" and "if liver enzymes rise"). Other reasons given were as follows: "affects treatment options", "it is standard with our cirrhosis clinic", "it is what I would do", "patients request it", "rule out liver lesion affecting laboratory values and so forth", and "recommendation by a consultant (gastroenterologist or hepatologist)". Other reasons given were as follows: transient population, screen the hepatitis C cirrhosis patients/not usually the alcoholic cirrhosis patients, not sure of the latest recommendations, see few cirrhotic patients and they usually are terminal or followed up by specialists, only check with hepatitis C, ultrasound often is performed as a diagnosis of cirrhosis evolving, usually do not live long enough, intend to but some slip through.
variables were associated significantly with recommending surveillance.
Discussion
Although formally recommended by hepatology societies for nearly a decade, less than half (25%-42%) of cirrhotic patients receive HCC surveillance according to several studies. [4] [5] [6] [7] Such low rates may occur because 20% to 50% of cirrhosis patients are not seen by gastroenterologists, who tend to recommend surveillance more than PCPs. 7, 8 Even after being seen by a gastroenterologist, patients may see their PCP more frequently, especially in remote regions where the distance to a subspecialist is greater. If surveillance is to ever have a sustainable rate greater than 50%, enlistment of PCP help probably will be necessary. However, data regarding PCP knowledge and beliefs about HCC surveillance are limited.
Our study indicates that only 45% of primary care providers who see cirrhosis patients in North Carolina recommend surveillance. Approximately 70% of PCPs who screen do so because they believe evidence supports it. Forty-two percent understood that some medical associations recommend it. Of the majority who do not screen, 84% deferred to subspecialists to recommend or consider surveillance, and 24% were unaware of surveillance recommendations. Only resection and transplantation were identified correctly as effective therapies by more than half of all respondents (67% and 56%, respectively) ( Table 4) . Only 35% identified radiofrequency ablation, even though data suggest it rivals resection in efficacy and is significantly less morbid. [15] [16] [17] Similarly, only a minority of PCPs identified transarterial chemoembolization and sorafenib despite randomized controlled trials (RCT) showing survival benefit. 18, 19 Those PCPs able to identify at least one effective treatment were twice as likely to recommend surveillance.
Of those who perform surveillance, ultrasound (US) and AFP, in combination, was used most commonly, and 12 months was the most common interval (Figures 1  and 2 ). These data may reflect older American Association for the Study of Liver Diseases recommendations from 2005 in which AFP was mentioned as an alternative option, if US was suboptimal or unavailable, and the suggested interval was up to 12 months. In 2010, the AFP measurement was eliminated completely and the interval was limited to 6 months.
Two studies reported higher rates of surveillance among PCPs (79%-89%), but the PCPs in these studies were highly biased toward increased HCC awareness. Both studies targeted PCPs from communities with high proportions of Asians, who have significantly higher prevalences of hepatitis B infection and consequent cirrhosis. In addition, PCPs in these studies may recommend surveillance more often because supporting evidence is stronger (Level I, RCT data) for surveillance in hepatitis B-related liver disease 20 than cirrhosis from other etiologies (Level II, observational, cohort data). 21 One study surveyed 11 San Francisco clinics with a patient population that is 25% Asian. 10 Moreover, 1 in 4 of the PCPs themselves were Asian and half had patient panels that were more than 25% Asian. The other study surveyed 3 Northern California counties, but again 1 in 4 of the PCPs were Asians, 43% spoke an Asian language, and 30% of their catchment was Asian. 9 Such PCP groups will have an increased interest in HCC surveillance compared with PCPs from other areas of the United States. The nation as a whole is only 5% Asian. 22 The only other study examining PCPs focused primarily on surveillance for hepatitis C and B infections.
11 HCC surveillance questions were limited and did not specify the presence or absence of cirrhosis. None of the 3 studies asked about HCC therapies or whether respondents actually see cirrhosis patients in their practices.
We focused on HCC surveillance and therapy. We surveyed a random sample of PCPs from across the state of North Carolina. Therefore, our data are more representative of communities with an Asian prevalence closer to the national average. Only 2.5% of North Carolina residents are of Asian descent. 13 Unlike prior surveys, we also asked whether PCPs actually saw cirrhosis patients in their practice. Such determination is critical because PCPs may render an opinion on HCC surveillance but never actually see a cirrhotic patient. Some may divert cirrhosis patients away from their clinic, or work in clinics in which cirrhosis patients are rare (eg, student health clinics).
We also wanted to understand PCP knowledge of HCC therapies because effective therapies are arguably the most compelling justification for surveillance. 1, 23 HCC therapies have evolved greatly in the past 12 years. Our survey suggests that PCP knowledge of more recently established treatments is relatively poor compared with established surgical interventions. Filling this knowledge gap regarding RCT data for transarterial chemoembolization, radiofrequency ablation, and sorafenib could increase surveillance rates by PCPs because the ability to identify at least one effective therapy independently doubled the odds of surveillance. Also, more than 80% of PCPs who do not screen deferred the decision to subspecialists, and despite some controversy in the literature regarding HCC surveillance recommendations, [23] [24] [25] only 8% did not screen because they felt the benefit was uncertain. Therefore, a large number of PCPs may recommend surveillance, if guidance and education are provided.
Our study was limited by a response rate (39%) that was lower than prior HCC surveillance surveys of PCPs (62%-71%). 9, 10 As mentioned, these prior studies targeted Asian community PCPs who very likely have a deeper knowledge and interest in HCC. Our response rate is more in line with less targeted provider surveys. An analysis of 130 surveys of US health care professionals, conducted from 1996 to 2005, yielded a median response rate of 51%, with an interquartile range of 38% to 65%. 26 Moreover, the response rate for health care professionals decreased significantly with the percentage of surveys having more than 60% response decreasing from 63% before 2000 to 35% in 2005 to 2008. 27 PCPs who see pertinence in a survey and have increased knowledge of the topic tend to respond more often, hence the higher response rates in the studies from California. 9, 10, 28 Such a response bias in our study would make our surveillance and knowledge of therapy rates overestimates of the true rate among PCPs in our state. Moreover, recall bias by those who said they recommend surveillance may overestimate the rate further.
Our survey also was limited in scope. The questionnaire was purposely kept brief to limit the nonresponse rate. Many other variables needed for a full behavior model such as PCP access to subspecialists and volume of cirrhotic patients seen were not included. Thus, therapy knowledge that was associated with surveillance may be merely a surrogate for other more pertinent variables not captured in our survey.
Our study provides data on HCC surveillance and knowledge of HCC therapy in an unselected population of PCPs who see cirrhotic patients in practices not enriched with Asians. The data suggest that HCC surveillance rates and knowledge of therapies are low. It also suggests an opportunity to increase community surveillance rates by closing the gap in knowledge, particularly regarding effective therapy options. Moreover, the majority of PCPs who do not screen may be amenable to surveillance if educated and guided by subspecialists. Enlisting PCP help in initiating surveillance may eliminate unnecessary referrals for opinion and certainly will help with sustaining surveillance once started. It is probably the only practical way to increase and sustain surveillance rates on a broader scale.
